Lupin's Generic Entresto Approved by USFDA, Set to Rival Novartis' Bestseller Farhat Nasim29 Jan 2025 8:04 PM ISTMumbai: In a fresh challenge to Novartis' blockbuster heart failure drug Entresto, Indian generics maker Lupin has received approval from the U.S....
Lupin receives USFDA approval for heart failure drug Ruchika Sharma24 Jan 2025 4:24 PM ISTMumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug Administration...
Novartis Entresto US patent upheld by US Court of Appeals Ruchika Sharma15 Jan 2025 3:30 PM ISTBasel: Novartis has announced that the Company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the...
Indian Pharma Market grows at 6.8 percent in October, Chronic Therapies Dominate: IQVIA Farhat Nasim19 Nov 2024 6:19 PM ISTNew Delhi: The Indian Pharmaceutical Market (IPM) experienced a significant 6.8% increase in Total Sales Audit (TSA) over the 12-month period ending...
Sacubitril/Valsartan Outperforms ACEI/ARB Therapy in Kidney Recovery for Thrombotic Microangiopathy: JAMA Medha Baranwal17 Nov 2024 9:00 PM ISTChina: A recent cohort study has suggested that sacubitril/valsartan may offer superior kidney function benefits for patients with thrombotic...
Sacubitril-Valsartan Improves Cardiac Function Despite Kidney Decline in HFrEF Patients, study reveals Medha Baranwal10 Nov 2024 9:00 PM ISTSouth Korea: A recent study published in Kidney Research and Clinical Practice has shed light on the impact of sacubitril-valsartan therapy on cardiac...
Sacubitril/Valsartan Safe to Continue Even with GFR Below 30 ml/min in HF Patients: Research Finds Dr. Garima Soni28 Oct 2024 10:57 AM ISTUSA: Recent research indicates that sacubitril/valsartan can be safely continued in heart failure patients, maintaining cardiovascular and kidney...
Exemed Pharmaceuticals gets CDSCO Panel nod to study Sacubitril plus Valsartan film-coated sustained release tablet Dr. Divya Colin4 Oct 2024 6:00 PM ISTNew Delhi: Reviewing the justification for the variability of the kinetic data of the bioequivalence (BE) study report of the fixed-dose combination...
USV Launches Sacubitril/Valsartan under Brand Name OnArni for Heart Failure Patients in India, Now Accessible & Affordable for All MD Brand Connect31 Aug 2024 11:30 AM ISTOnArni 50mg priced at just INR 8/-per tablet is now accessible and affordable for all Indian heart failure patients. OnArni stands out by virtue of...
Justify proposed dose and rationality: CDSCO Panel Tells Lupin on FDC Sacubitril plus Valsartan Dr. Divya Colin5 Aug 2024 6:00 PM ISTNew Delhi: In response to the justification presented by the drug major Lupin on the rationality of the fixed-dose combination (FDC) cardiovascular...
USFDA nod to Zydus Lifesciences chronic heart failure drug Ruchika Sharma10 July 2024 5:20 PM ISTSacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization.
New drug shows potential benefits in recovery of patients after a heart attack, suggests research Dr. Kamal Kant Kohli21 May 2024 8:00 PM ISTResearchers from the Cardiac Regeneration and Heart Failure Research Group (ICREC) at the Germans Trias i Pujol Research Institute (IGTP) and the...
